On July 6, Innovent Biologics rose 3.19% in regular trading, trading at HKD 91.35/share, with turnover of HKD 416 million, extending its recent strong momentum.

On the news front, multiple catalysts continue to drive sentiment. On June 30, Innovent signed a commercialization agreement with Eli Lilly for CDK4/6 inhibitor Verzenios (abemaciclib) in mainland China, granting Innovent exclusive rights to import, market, and distribute the drug, strengthening its breast cancer commercial portfolio. Additionally, core product mazdutide passed the National Healthcare Security Administration's preliminary review for medical insurance catalog inclusion on June 29, a key step toward reimbursement coverage. The company also launched its South China warehouse on July 1, further enhancing supply chain capabilities.

Within the Biotechnology sector, broad strength provided additional support. Among peers, 3SBio rose 5.06%, Remegen rose 5.01%, SKB Bio rose 3.01%, Akeso rose 2.83%, and BeiGene rose 1.64%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)